IRB 21257: Evaluation of TAK-981 and TAK-981 Combinations Following Intratumoral CIVO Microdosing in Patients with Head and Neck Cancer

IRB 212805: A Phase 0 Master Protocol Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients with Solid Tumors

IRB 17753: Keynote 689: A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

IRB 19518: A Phase 1B Multi-center pharmacodynamic study to assess the effects of multiple study drug regimens in subjects with newly diagnosed locally advanced head and neck squamous cell carcinoma

IRB 00021902: A Digital Intervention Protocol to Enhance Recovery after Head and Neck Surgery: A Randomized Controlled Trial

IRB 23008: Gilead A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

IRB 23008: Gilead A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

IRB 23008: Gilead A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

IRB 23008: Gilead A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma

IRB 00021902: A Digital Intervention Protocol to Enhance Recovery after Head and Neck Surgery: A Randomized Controlled Trial

CROSS-DISEASE TRIALS:

IRB 00021902: EAY131 (MATCH)

http://www.ohsu.edu/research/rda/so/knight.php